Influence of Standardized Extract Ginkgo biloba EGb761® Towards Quality of Life Indicators in Patients with Diabetes Mellitus Type 2
- 54 Downloads
Cognitive impairment in patients with type 2 diabetes mellitus (DM-2) currently attracts a lot of attention due to their impact on quality of life and the effectiveness of treatment. The aim of research is to find the most effective medication which influences the cognitive functions positively. The research included 120 patients with average age of 61.22 ± 8.6 and average DM-2 duration of 10.84 ± 8.2 years. Mini Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA test), Trail Making Test (TMT), Parts A and B, Hospital Anxiety and Depression Scale (HADS), and The Short Form-36 (SF-36) were used. It was revealed that patients with DM type 2 had cognitive dysfunction generally presented by mild cognitive impairment. Patients with DM-2 have an early manifestation of cognitive impairment. After the initial estimation of indicators, all the patients were taking standardized extract Ginkgo biloba (EGb 761®) in the dose 240 mg a day for 6 months. Estimation of all the indicators after 3 and 6 months of treatment showed significant cognitive improvement. By matching the available experimental and clinical data, we can conclude that in the setting of DM-2 EGb 761®, by producing a positive effect towards various factors which results from insulin resistance of the brain, improves functions of the brain, which manifests in improvement of main QoL indicators in DM-2.
KeywordsDiabetes mellitus type 2 Cognitive decline EGb 761 Quality of life Neurocognitive tests
The reported study was supported by the program of competitive growth of Kazan Federal University.
- 1.Global report on diabetes. [Internet]. Apps.who.int. 2018 [cited 27 March 2018]. Available from: http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf.
- 2.Quality of Life Assessment: an annotated bibliography [Internet]. Apps.who.int. 1994 [cited 27 March 2018]. Available from: http://apps.who.int/iris/bitstream/10665/61629/1/WHO_MNH_PSF_94.1.pdf.
- 6.MoCA Montreal—cognitive assessment [Internet]. MoCA Montreal—cognitive assessment. [cited 27 March 2018]. Available from: http://www.mocatest.org/wp-content/uploads/2015/tests-instructions/MoCA-Test-Russian_2010.pdf.
- 9.Ware, J., Snow, K., Kosinski, M., & Gandek, B. (1997). SF-36 health survey. Boston: The Health Institute, New England Medical Center.Google Scholar
- 17.Talbot, K., Wang, H., Kazi, H., Han, L., Bakshi, K., Stucky, A., et al. (2012). Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. Journal of Clinical Investigation, 122(4), 1316–1338.CrossRefGoogle Scholar
- 18.Blazquez, E., Velazquez, E., Hurtado-Carneiro, V., Ruiz-Albusac, J. (2014). Insulin in the brain: its pathophysiological implications for states related with central insulin resistance, type 2 diabetes and Alzheimer’s disease. Frontiers in Endocrinology, 5.Google Scholar
- 19.Derakhshan, F., & Toth, C. (2013). Insulin and the brain. Current Diabetes Reviews, 9(2), 102–116.Google Scholar
- 21.EGb 761 prevented palmitate-induced insulin resistance in L6 myotubes via the inhibition of stress kinases, NF-[kappa]B, and PK [theta] | American Diabetes Association [Internet]. Professional.diabetes.org. 2007 [cited 30 March 2018]. Available from: https://professional.diabetes.org/abstract/egb-761-prevented-palmitate-induced-insulin-resistance-l6-myotubes-inhibition-stress.
- 22.Kudolo, G., Wang, W., Javors, M., & Blodgett, J. (2006). The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects—a double blind placebo-controlled, crossover study. Clinical Nutrition, 25(4), 606–616.CrossRefGoogle Scholar
- 26.Kehr, J., Yoshitake, S., Ijiri, S., Koch, E., Nöldner, M., & Yoshitake, T. (2012). Ginkgo biloba leaf extract (EGb 761®) and its specific acylated flavonol constituents increase dopamine and acetylcholine levels in the rat medial prefrontal cortex: possible implications for the cognitive enhancing properties of EGb 761®. International Psychogeriatrics, 24(S1), S25–S34.CrossRefGoogle Scholar
- 28.Gavrilova, S., Preuss, U., Wong, J., Hoerr, R., Kaschel, R., & Bachinskaya, N. (2014). Efficacy and safety of Ginkgo biloba extract EGb 761®in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial. International Journal of Geriatric Psychiatry, 29(10), 1087–1095.CrossRefGoogle Scholar
- 29.Hoerr, R., Nacu, A. (2016). Neuropsychiatric symptoms in dementia and the effects of Ginkgo biloba extract EGb 761® treatment: Additional results from a 24-week randomized, placebo-controlled trial. Open Access Journal of Clinical Trials, 1.Google Scholar